Systematic analysis of copy number variation associated with congenital diaphragmatic hernia. by Zhu, Qihui et al.
The Jackson Laboratory
The Mouseion at the JAXlibrary
Faculty Research 2018 Faculty Research
5-15-2018
Systematic analysis of copy number variation
associated with congenital diaphragmatic hernia.
Qihui Zhu
The Jackson Laboratory, qihui.zhu@jax.org
Frances A High
Chengsheng Zhang
The Jackson Laboratory, chengsheng.zhang@jax.org
Eliza Cerveira
The Jackson Laboratory, eliza.cerveira@jax.org
Meaghan K Russell
See next page for additional authors
Follow this and additional works at: https://mouseion.jax.org/stfb2018
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Faculty Research at The Mouseion at the JAXlibrary. It has been accepted for inclusion in
Faculty Research 2018 by an authorized administrator of The Mouseion at the JAXlibrary. For more information, please contact
Douglas.Macbeth@jax.org.
Recommended Citation
Zhu, Qihui; High, Frances A; Zhang, Chengsheng; Cerveira, Eliza; Russell, Meaghan K; Longoni, Mauro; Joy, Maliackal P; Ryan,
Mallory; Mil-Homens, Adam; Bellfy, Lauren; Coletti, Caroline M; Bhayani, Pooja; Hila, Regis; Wilson, Jay M; Donahoe, Patricia K;
and Lee, Charles, "Systematic analysis of copy number variation associated with congenital diaphragmatic hernia." (2018). Faculty
Research 2018. 122.
https://mouseion.jax.org/stfb2018/122
Authors
Qihui Zhu, Frances A High, Chengsheng Zhang, Eliza Cerveira, Meaghan K Russell, Mauro Longoni,
Maliackal P Joy, Mallory Ryan, Adam Mil-Homens, Lauren Bellfy, Caroline M Coletti, Pooja Bhayani, Regis
Hila, Jay M Wilson, Patricia K Donahoe, and Charles Lee
This article is available at The Mouseion at the JAXlibrary: https://mouseion.jax.org/stfb2018/122
Systematic analysis of copy number variation
associated with congenital diaphragmatic hernia
Qihui Zhua,1, Frances A. Highb,c,d,1, Chengsheng Zhanga,1, Eliza Cerveiraa, Meaghan K. Russellb, Mauro Longonib,d,
Maliackal P. Joyb, Mallory Ryana, Adam Mil-homensa, Lauren Bellfya, Caroline M. Colettib, Pooja Bhayanib, Regis Hilab,
Jay M. Wilsonc,d, Patricia K. Donahoeb,d,2,3, and Charles Leea,e,2,3
aThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032; bPediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston,
MA 02114; cDepartment of Surgery, Boston Children’s Hospital, Boston, MA 02115; dHarvard Medical School, Boston, MA 02115; and eDepartment of Life
Sciences, Ewha Womans University, Seoul 03760, South Korea
Contributed by Patricia K. Donahoe, April 4, 2018 (sent for review August 22, 2017; reviewed by Sally A. Camper and Deborah Krakow)
Congenital diaphragmatic hernia (CDH), characterized by malfor-
mation of the diaphragm and hypoplasia of the lungs, is one of the
most common and severe birth defects, and is associated with high
morbidity and mortality rates. There is growing evidence demon-
strating that genetic factors contribute to CDH, although the patho-
genesis remains largely elusive. Single-nucleotide polymorphisms
have been studied in recent whole-exome sequencing efforts,
but larger copy number variants (CNVs) have not yet been studied
on a large scale in a case control study. To capture CNVs within
CDH candidate regions, we developed and tested a targeted array
comparative genomic hybridization platform to identify CNVs within
140 regions in 196 patients and 987 healthy controls, and identified
six significant CNVs that were either unique to patients or enriched
in patients compared with controls. These CDH-associated CNVs
reveal high-priority candidate genes including HLX, LHX1, and HNF1B.
We also discuss CNVs that are present in only one patient in the cohort
but have additional evidence of pathogenicity, including extremely
rare large and/or de novo CNVs. The candidate genes within these
predicted disease-causing CNVs form functional networks with other
known CDH genes and play putative roles in DNA binding/transcription
regulation and embryonic development. These data substantiate the
importance of CNVs in the etiology of CDH, identify CDH candidate
genes and pathways, and highlight the importance of ongoing anal-
ysis of CNVs in the study of CDH and other structural birth defects.
copy number variant | CNV | customized array | birth defects |
congenital diaphragmatic hernia
Congenital diaphragmatic hernia (CDH) is one of the mostcommon and lethal congenital anomalies. It has an incidence
of ∼1 in 3,000 live births (1–4) and occurs when the diaphragm
does not form properly, often resulting in displacement of the
abdominal contents into the chest cavity. CDH arises during
prenatal development and is almost always accompanied by lung
hypoplasia and pulmonary hypertension, which are the major
causes of morbidity and mortality. The lung hypoplasia is ap-
parent before displacement of abdominal contents into the chest
cavity in certain animal models, suggesting that a primary defect
in lung development plays an important role in this disease. With
advanced medical and surgical care, the survival rate for these
infants can reach 80%, but worldwide mortality is 50%. Long-
term morbidity among survivors is common (5).
The genetic contributions to congenital diaphragmatic defects
are heterogeneous, with mutations in many different genes capable
of generating the same phenotype (4), which makes interpretation
of genomic data from patients with CDH more challenging. While
some of the genetic mutations that result in CDH impair only
formation of the diaphragm, several genes and pathways are also
required for normal development of the lungs and its vasculature.
More than 70 genes are now implicated in CDH based on analysis
of the genomes of patients with CDH as well as the character-
ization of mutant mice (6–12). Many CDH genes discovered from
mouse models were also later found to harbor rare and predicted
pathogenic mutations in patients with CDH (8, 10, 13).
Numerous studies have implicated copy number variants
(CNVs) in human disease with associated phenotypes ranging
from cognitive disabilities to predispositions to obesity, cancer, and
other diseases (14–17). Both inherited and de novo CNVs play a
causative role in CDH (18–22), and at least 10% of CDH cases are
estimated to be caused by genomic imbalances (21). Several re-
current genomic imbalances (i.e., deletions and duplications) have
been found in specific chromosomal regions, including 1q41–42,
8p23.1, 8q23, and 15q26 (19, 22–25), and analysis of these regions
has led to the identification of validated CDH genes (7, 8, 26).
However, many other genomic imbalances have only been de-
scribed in one or two patients with CDH, making conclusions
about causation difficult, especially without the knowledge of the
frequency of these CNVs among healthy individuals.
The aim of this study was to perform a systematic analysis of
CNVs in a large number of patients with CDH alongside a large
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control cohort to provide further evidence for specific putative
CDH genes in the etiology of this condition. We designed a cus-
tomized high-resolution CNV array, targeting known and candidate
genomic regions associated with diaphragmatic defects. This cus-
tomized array was used to interrogate the genomes of 196 patients
with CDH and 987 controls to identify CNVs that are significantly
associated with CDH risk. An ethnically matched control cohort
was used to provide additional statistical confirmation of significant
association for each region. As a result, we have identified six CNVs
that are significantly associated with CDH and encompass genes
involved in DNA binding/transcription regulation and embryonic
organ development. These findings support a critical role for CNVs
in the pathogenesis of a significant subset of patients with CDH,
indicating the importance of assessing CNVs as well as sequence
variants in the genetic analyses of these patients.
Results
CDH Patient and Control Selection. We analyzed DNA samples
from 196 patients with CDH (SI Appendix, Table S1). A total of
96 individuals (49%) had isolated CDH, and 80 individuals
(40%) had complex phenotypes including additional congenital
anomalies or other unusual features. The remaining cases did
not have sufficient phenotype information to classify as isolated
or complex. Among the complex cases, congenital heart disease
and neurodevelopmental disorders were the most common co-
occurring morbidities. Left-sided Bochdalek hernia was the most
common specified type of diaphragm defect (n = 70). Because
our intention was to detect all CNVs for an unbiased statistical
analysis, patients with confirmed findings on clinical or research
arrays were not excluded from the study.
To select proper normal control samples to minimize the
ethnic background bias for this study, we performed a principal-
component analysis (PCA) using whole-exome sequencing
(WES) data on CDH cases (8) and whole-genome sequencing
data from presumed healthy population samples from the 1000
Genomes Project (27). By this method, 987 population controls
were selected for our study to match ancestries between cases
and controls (SI Appendix, Fig. S1). These controls represented
26 populations, although since we collected the majority of our
patients with CDH from North America, more ethnically matched
controls from Europe (494) and admixed Americans (120) were
selected for this study.
CNVs Detected from Customized Array. A customized array com-
parative genome hybridization (aCGH) platform was designed
covering 140 known and candidate CDH regions (Fig. 1 and SI
Appendix, Table S2) (see details in SI Appendix, Supplemental
Materials and Methods). We completed aCGH experiments on
196 patients with CDH, 987 population-matched control samples,
and 109 unaffected parents for a total of 1,292 individuals. In total,
234 gains and 437 losses were detected from all of the samples (SI
Appendix, Table S3). The median number of CNVs detected per
sample was 13, and they ranged in size from 0.4 kb to 95 Mb
(median, 2.1 kb; average, 119 kb). The majority of CNVs identi-
fied were within the 1- to 10-kb range, and there was no significant
difference in the size distribution among CDH patients, their
parents, and population controls (SI Appendix, Fig. S2).
Identification of Statistically Significant CNVs Enriched in Patients
with CDH. To identify significant CNVs associated with CDH,
we compared the frequency of CNVs in patients with the fre-
quency in ethnically matched controls. We identified six CNVs
that were present in two or more patients and at a significantly
higher frequency in cases than in controls (Table 1). Three of
these CNVs were found in two or more patients with CDH but not
in any population controls. First, a 1.6-kb gain involving the HLX
gene was found in five patients with CDH (Table 1, P = 0.00058,
Fisher’s exact test). This duplication encompasses most of exon
1 and part of intron 1 (Fig. 2A). HLX homozygous null mice have
been previously reported to have diaphragmatic defects and the
gene is expressed in the developing murine diaphragm (28, 29).
Second, a 1.5-Mb loss within the chromosome 17q12 target region
was found in two unrelated patients with CDH (Fig. 2B). This
deletion is predicted to cause haploinsufficiency for 15 protein-
coding genes, two noncoding transcripts, and two microRNAs
(Fig. 2B and Table 1). The P value of this CNV slightly missed the
significance threshold (P = 0.06) due to a relatively small sample
size, although we still include it as a significant candidate because
it is large in size, has been described previously in three other
published cases of CDH (21, 30), and it is absent from control
CNV databases. Third, a 113-kb loss from chromosome region
1q44 was found in three patients (P = 0.016), encompassing the
ZNF672, ZNF692, and PGBD2 genes (Fig. 2C and Table 1). We
also identified three CNVs in multiple patients with CDH and in
one or more controls, but at frequencies significantly higher among
patients compared with ethnically matched controls (Table 1). A
2.4-Mb gain at 16p11.2 was detected in 4 of 196 patients with CDH
and 4 of 987 controls and was significantly associated with CDH
(P = 0.047). This region encompasses the protein-coding genes
TP53TG3E, TP53TG3B, TP53TG3F, and TP53TG3C, two non-
coding transcripts, and several pseudogenes. Also, a 131-kb loss at
4p16.3 was identified in five patients with CDH and one ethnically
matched control (P = 0.001), overlapping two zinc finger genes of
unknown function, ZNF595 and ZNF718. Larger deletions, in-
cluding this region, have been reported to be associated with
Wolf–Hirschhorn syndrome with CDH (31, 32). Finally, a 79-kb
loss at 5p15.2 was found in three patients with CDH and three
controls (P = 0.04) and encompasses one noncoding RNA gene,
LINC01194. The function of LINC01194 is unknown, but it is
reported to be expressed in both skeletal muscle and lung, relevant
tissue types for the pathogenesis of CDH (GTex) (33). This CNV
was also detected in several controls from different ethnicities,
suggesting that it may have a higher frequency in other populations
without a significant association with CDH. We compared the
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Fig. 1. Customized array targeted for CDH candidate regions. (A) Map of
genes and genomic regions covered by custom array. Blue bars indicate
known and candidate genomic regions implicated in human CDH. Red as-
terisks indicate other CDH candidate genes. (B) The light blue section shows
different lengths of the targeted CDH regions, and the dark blue section
represents different probe densities designed for the targeted regions. The
orange bars represent regions flanking CDH targets, and the yellow bars
represent the backbone for the rest of the human genome.
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phenotypes of patients with significant recurrent CNVs (SI Ap-
pendix, Table S4). Two of three patients with 1q44 deletions had
colobomas in addition to CDH, although we did not identify any
other major genotype–phenotype correlations.
The custom array also detected eight chromosomal aberra-
tions greater than 1 Mb in size in patients that were absent from
controls. Each of these CNVs was present only in a single patient
and thus did not reach statistical significance. However, we feel
that they are likely to be pathogenic based on size alone (Table
2). Not surprisingly, these patients tended to have other mal-
formations or medical problems in addition to CDH. All of these
chromosomal abnormalities were confirmed by clinical karyo-
type, clinical microarray, digital droplet PCR (ddPCR), and/or
read depth data from WES.
To assess the performance of the customized array, we tested
all 6 significantly associated CNVs from Table 1, 4 large singleton
CNVs from Table 2, and 14 other randomly chosen CNVs for
validation using ddPCR; all 6 significant CNVs and 4 large CNVs
were validated (SI Appendix, Fig. S3). In total, ∼87.5% (21/24) of
the chosen CNVs were successfully validated. The CNVs that
failed ddPCR were relatively small deletions or duplications with a
limited number (7, 5) of probes, which is low coverage compared
with most other candidate regions on the array. Overall, our re-
sults indicate that CNVs determined by ddPCR were highly cor-
related with the CNV data obtained by the custom array.
Including the six statistically significant CNVs (Table 1), the
estimated frequency of likely causative CNVs in this cohort is 19/
196 (9.7%). If we also include large (>1 Mb) CNVs that are
present in only one patient but are suspected to be pathogenic
based on their size alone (Table 2), then this frequency is 25/196
(13%). This frequency is slightly higher than reported in previous
studies (21), although this may be at least partially explained by
the higher resolution over CDH candidate regions compared
with conventional aCGH.
Analysis of de Novo CNVs in Patients with CDH. To detect de novo
CNVs, we also used the custom array to study parental sam-
ples from a subset of patients, providing data on a total of 37
proband-parent trios. Among the de novo CNVs detected were
several of statistically significant CNVs, including a deletion at
1q44 and a duplication at 16p11.2 (SI Appendix, Table S4). In ad-
dition, a 48.8-Mb duplication at 11q13.2–q23.2 and a 12.3-Mb
deletion at 3p26.3–p25.2 (Table 2) were validated as de novo CNVs
by ddPCR in this study. The observation that some of these CDH-
associated CNVs are de novo further supports their pathogenicity.
We detected several other de novo CNVs, each present in one
patient and absent in controls, although these were small and in
gene-poor regions so their clinical significance is unclear. Several
other CNVs that appeared de novo in probands with CDH were
also found in many control samples, suggesting that these may be at
regions of high mutation rate (i.e., hot spots for CNV formation).
Pathway Analysis and Functional Interaction Network Study. To
understand better the biological functions of the genes within
significantly CDH-associated CNVs, we performed Gene On-
tology and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analysis on 41 unique RefSeq genes within
the six CNVs significantly associated with CDH (Table 1). Key
functions of these genes included DNA binding/gene transcrip-
tion regulation (e.g., AATF, HLX, HNF1B, LHX1, TADA2A, and
ZNF718), embryonic organ development (e.g., HLX, TADA2A,
HNF1B, and LHX1), and metabolic pathways (e.g., ACACA and
PIGW) (SI Appendix, Table S5).
In addition, we examined the direct protein–protein interactions
and indirect functional associations involving these 41 genes by
STRING analysis (34), as well as protein–protein interactions using
InWeb (35). We identified two networks using STRING analysis (SI
Appendix, Fig. S4), one consisting of 13 genes also identified by the
pathway analysis and the second including the LHX1 and HNF1B
genes. Eleven genes have transcription regulatory function but do not
have known interactions with any other genes within the cluster (data
not shown). Protein–protein interaction network analysis using
InWeb (35) identified two candidate genes from the 17q12 region
that interact with other known CDH genes or pathways: LHX1
(which interacts with the known CDH genes GLI2/3) and ACACA
(which interacts with the cohesin complex, which includes the caus-
ative genes for the CDH-associated Cornelia de Lange syndrome).
Integration with Gene Expression Datasets and WES Data. We in-
tegrated these results with gene expression datasets from the
developing mouse diaphragm and lung (11, 36). This approach
has been highly successful in the identification of CDH-causing
genes (10, 11). Of the protein-coding genes within the significant
CNV regions, several are highly expressed in the developing
Table 1. Summary of the significant CNVs detected in multiple patients with CDH
No. of samples affected
Region (hg19) Size, bp Cytoband CNV type
Proband
(n = 196)
Population
(n = 987) P value Description/gene(s)
i) CNVs detected in two or more patients but not in population controls
chr1:221052740–
221054346
1,606 1q41 Gain 5 0 0.00058** Most of exon 1 and part of intron
1 of the HLX gene, as well as
noncoding RNA gene HLX-AS1
chr17:34813719–36278623 1,464,904 17q12 Loss 2 0 0.06 AATF, ACACA, DDX52, DUSP14,
GGNBP2, HNF1B, LHX1, MYO19,
DHRS11, MRM1, c17orf78, PIGW,
SYNRG, TADA2A, and ZNHIT3
chr1:249126046–
249238916
112,870 1q44 Loss 3 0 0.016* ZNF672, ZNF692, and PGBD2
(overlaps terminal region of
1q21.1–q44 duplication)
ii) CNVs found in multiple patients with CDH but at frequency higher than ethnically matched control populations
chr16:32403182–34759850 2,356,668 16p11.2 Gain 4 4 0.047* TP53TG3E, TP53TG3B, TP53TG3F,
TP53TG3C
chr4:11942–143314 131,372 4p16.3 Loss 5 1 0.001** ZNF595 and ZNF718. Overlaps with
Wolf–Hirschhorn critical region
chr5:12674767–12754177 79,410 5p15.2 Loss 3 3 0.036* LINC01194 (noncoding)
The reference genes that overlap with the significant CNVs are in bold. Significance level: *P < 0.05 and **P < 0.01.
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murine diaphragm as well as in murine lungs during critical
stages of development (Table 3).
We also examined WES data on a cohort of 275 patients with
CDH (8) to identify sequence variants in genes within recurrent
CNVs (Table 3). Eleven of the protein-coding genes, and one
noncoding gene (ZNF595) harbor rare (<0.1% allele frequency
in control populations), predicted pathogenic variants (including
frameshift, stop gain, essential splice site variants, as well as mis-
sense variants predicted to be pathogenic by multiple in silico
algorithms) (Table 3 and SI Appendix, Table S6), providing
additional support that these genes may function independently
as CDH risk genes. The 17q12 deletion region contains several
highly constrained genes predicted to be intolerant of hap-
loinsufficiency (ExAc pLi > 0.9). Among these constrained
genes, sequence variants were also identified in GGNBP2 and
SYNRG (Table 3).
Discussion
In this study, we have developed a high-resolution customized
CNV array targeting genomic regions that contain known or
candidate CDH genes, and have identified six recurrent CNVs
that are significantly enriched in patients with CDH compared
with ethnically matched controls. This customized array was
chosen to provide improved coverage of CDH candidate regions
to overcome the relatively low resolution of commercially
available genome-wide aCGH platforms, allowing for identifi-
cation of small CNVs that would have been missed on a standard
aCGH (such as the recurrent 1.6-kb duplication at the HLX lo-
cus). This customized array also provided a cost-effective ap-
proach that allowed direct case control comparisons using the
same platform to validate with statistical significance of the
contribution of these genomic regions to CDH. By studying
196 patients with CDH and 987 normal controls, this is the
largest patient cohort study evaluating genomic structural ab-
normalities associated with CDH undertaken to date. The sig-
nificant CNVs identified in this study validate several CDH
genes and genomic regions and identify additional candidate
genes and pathways that contribute to the pathogenicity of CDH.
This study establishes 17q12 as a significant CNV associated
with CDH, providing additional evidence that this is a true
chromosomal hot spot for CDH. The 17q12 deletions from our
study have more than 80% overlap with deletions reported by
previous studies (21, 30, 37). By comparing these cases, we were
able to narrow the minimum critical region to 1.22 Mb (Fig. 2B),
containing nine protein-coding genes (LHX1, AATF, ACACA,
C17orf78, TADA2A, DUSP14, SYNRG, DDX52, and HNF1B).
Lim Homeobox 1 (LHX1) was initially suggested to be associated
with CDH based on gene enrichment analysis (21). Our protein
network analyses show multiple interactions between genes
within this deletion hot spot as well as between these and other
known CDH genes and pathways. For example, LHX1 may in-
teract with HNF1 homeobox B (HNF1B) (SI Appendix, Fig. S4).
HFN1B is involved in the WNT signaling pathway (38), which is
important in mesodermal differentiation, a key component of
proper diaphragm formation (39). Both LHX1 and HNF1B are
homeobox genes that play multiple critical roles in organ de-
velopment (40–42). The network analyses support a model in
which the genes within the 17q12 hot spot may function together
and/or in cooperation with other CDH genes and pathways in the
orchestration of diaphragm and/or lung development.
The most common CDH-associated CNV in this study was a
recurrent duplication in the HLX gene found in five patients but
no controls, or ∼2.5% of this cohort. HLX is a member of the
homeobox family of transcription factors that is located within
the chromosome 1q41–1q42 region, a deletion hot spot for CDH.
There are multiple lines of evidence suggesting that HLX is an
important CDH candidate gene, including developmental ex-
pression patterns (11, 36) and bioinformatics functional associa-
tion analyses (43). In addition, HLX homozygous null mice have
diaphragmatic defects (28, 29, 44). HLX is a putative target for
NR2F2 (COUP-TFII) (ENCODE), a transcriptional repressor of
the retinoic acid signaling pathway (SI Appendix, Fig. S5), and an
established CDH risk gene in both humans and mouse models (13,
45). We, and others, have shown previously that sequence variants
in the HLX gene are present at low frequency in patients with
CDH (8, 44), but this study demonstrates that duplications of this
gene may be a common mutation mechanism important to the
etiology of CDH. The mechanism by which recurrent HLX du-
plications may result in CDH is still unclear, although we hy-
pothesize that the partial gene duplication may disrupt the coding
region and/or splicing. There is also an antisense transcript in this
region (HLX-AS1) that may have regulatory functions. Further
experiments will be necessary to delineate the functional conse-
quence of these duplications on HLX and HLX-AS1 expression
and to assess for perturbations of relevant developmental path-
ways including retinoic acid signaling (SI Appendix, Fig. S5).
The remaining four statistically significant CDH-associated
CNVs from this study identify several other novel candidate
genes including ZNF672, ZNF692, PGBD2, TP53TG3, and
A
B
C
Fig. 2. Depiction of significant CNV regions. For CNVs, red bars represent loss
and blue bars represent gain. (A) The 1q41 CNVs involving the HLX gene. Black
boxes represent exons, white boxes are introns, and gray boxes are the un-
translated regions. The numbers on the top of the genes indicate chromosomal
coordinates (hg19/GRCH37). Blue lines indicate the relative positions of the du-
plications in our five patients with CDH. The 3′ end of the noncoding RNA gene,
HLX-AS1, overlaps with the 1q41 duplication as shown. The open arrow indicates
the 5′ of this gene is beyond the range of this figure. (B) The 17q12 deletions
from two patients (dark red bars) in our study as well as three patients (light red
bars) from previous studies (21, 30). The x axis indicates the genomic location,
and the y axis indicates the log2 ratio from the array. The dots indicate probe
intensities in this region of the array. LHX1, ACACA, and HNF1B (in bold) are
candidate CDH genes in this CNV. (C) The 1q44 deletions from three patients
(dark red bars) in our study. Four published cases of deletions (blue bars) and
duplications (light red bars) in the neighboring region are also indicated.
5250 | www.pnas.org/cgi/doi/10.1073/pnas.1714885115 Zhu et al.
ZNF595. There is very little information known about the
function or developmental expression patterns of these genes
in the embryonic diaphragm or lung, although ZNF672,
ZNF692, PGBD2, and ZNF595 are expressed in adult skeletal
muscle and lung (GTex) (33). Further studies will be neces-
sary to understand if and how they play a role in the patho-
genesis of CDH.
The results of this study support the hypothesis that CNVs
make a significant contribution to the pathogenesis of diaphrag-
matic defects and provide a model that may be applied to other
structural birth defects. Future analyses of CNVs in CDH, either
through application of this customized targeted array or through
other platforms such as whole-genome sequencing, will be applied
to additional CDH cohorts to validate the CNVs identified in this
manuscript and to identify other novel CNVs. Also, we propose
that functional studies on the CDH candidate genes prioritized
through this CNV analysis will provide additional insight into the
pathogenesis of CDH and identify pathways for the future de-
velopment of targeted therapeutics for this severe and often lethal
birth defect.
Materials and Methods
Patient and Control Sample Selection. In total, 196 patient samples and 109
parental sampleswere collected as part of the study “GeneMutation and Rescue
in Congenital Diaphragmatic Hernia” and were recruited at Massachusetts
General Hospital and Boston Children’s Hospital, and via outside referrals
from other clinicians or family support groups. Informed consent, blood,
and tissue samples were obtained according to Partners Human Research
Committee and Boston Children’s Hospital clinical investigation standards
(Protocol 2000P000372 and 05-07-105R, respectively). Each individual un-
derwent a detailed phenotypic analysis including review of the medical
record, family history (46), and, whenever possible, physical examination by
the study geneticists.
The 987 population control samples were chosen from the phase 3 DNA
samples of the 1000 Genomes Project (27). Samples were selected as ethni-
cally matched to the patient samples based on PCA of variants in already
available whole-exome and/or whole-genome data. Concordant SNPs pre-
sent in both groups were selected using the selectvariant function from
GATK (47) and converted into binary file by Plink (48). PCA weights were
computed by Plink and GCTA software (49).The first 20 principal compo-
nents from all samples were generated and plotted in an R program (50) (see
Results for more details). Population control samples were purchased from
the Coriell Institute for Medical Research.
Customized aCGH Design, Hybridization, and Data Analysis. The customized
aCGH includes 140 target regions containing known or candidate genes for
CDH (Fig. 1A and SI Appendix, Table S6). The regions targeted included the
following: (i) regions of previously published recurrent chromosomal dele-
tions or duplications in two or more patients with CDH, usually detected by
lower resolution platforms (19, 21, 22, 24, 51–55); (ii) genes identified
through human genomic studies on CDH and monogenic syndromic disor-
ders associated with CDH (4, 6–9); (iii) genomic regions from preliminary
studies from our laboratory; (iv) genes identified as causative of diaphragm
defects and/or lung hypoplasia in mouse models; and (v) candidate genes
prioritized from analyses of gene expression in normal mouse embryonic
Table 2. Specific singleton CNVs (>1 Mb)
Genomic coordinates (hg19) Loss/gain Size, Mb Patient ID Phenotype Confirmatory testing
chr4:43284–49244506 Gain 49.2 C119 Hypoplastic left heart syndrome,
stillbirth
Karyotype: 47, XX, +der(4)t(4,5)(q21; q35)
chr4:52742992–70765489 Gain 18.2
chr5:177047523–180699183 Gain 3.6
chr11:65440233–114273551 Gain 48.8 C146 Multiple congenital anomalies,
additional details unknown
Confirmed by ddPCR and read depth data from
WES
chr18:52948800–77967778 Loss 25.0 C5 Morgagni hernia, cleft palate,
brachydactyly, dysmorphisms,
short stature, microcephaly,
moderate developmental delay
Confirmed by ddPCR and karyotype: 46, XX,
del(18)(q21.2)
chr3:66478–12304371 Loss 12.2 C86 Seizures, partial agenesis of corpus
callosum, dysmorphic facial
features
Confirmed by ddPCR and clinical aCGH: del
3p26.3-p25.2
chr15:93825922–102465355 Loss 8.6 C148 Multiple congenital anomalies,
additional details unknown
Karyotype: 46, XX, der(15)t(1;15)(q44; q26.3)mat
chr16:14714766–18844674 Gain 4.1 C158 No phenotypic data available Confirmed by ddPCR and read depth data from
WES
Table 3. Selected prioritized candidate genes from CDH-associated CNV regions
Region Gene
Embryonic diaphragm
expression
Lung expression
(peak stage)
Constraint
(ExAC pLI)
No. sequence variants
(in 275 probands)*
dup 1q41 HLX High Alveolar 0.56 1
del 17q12 ACACA Low Embryonic/
alveolar
1.00 0
DUSP14 High Alveolar 0.77 0
GGNBP2 High — 1.00 1
HNF1B Low Saccular/alveolar 1.00 0
LHX1 Low — 0.29 0
SYNRG Low Alveolar 0.97 2
Diaphragm expression indicates whether a gene is expressed above (“high”) or below (“low”) the median
normalized hybridization intensities for intronic probes based on expression microarrays from the embryonic
mouse diaphragm (11). Lung expression indicates the peak developmental stage of expression levels in mouse
lungs, and “—” indicates this gene is not highly expressed in lung (36).
*Number of sequence variants in each gene that are rare (<0.1% in control populations) and predicted
pathogenic (by SIFT, PolyPhen) in a cohort of 275 patients with CDH studied with WES.
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diaphragms (11) and protein–protein interaction analyses with known CDH
genes and pathways (8).
The customized 60K Agilent aCGH platform was designed to obtain op-
timal coverage and yield high-quality data. The probe density and distri-
bution varied in accordance with the target region size (Fig. 1B and SI
Appendix, Supplemental Materials and Methods). The array design was
tested for reproducibility and quality before use. Protocols for aCGH hy-
bridization and data analysis are available in SI Appendix, Supplemental
Materials and Methods.
CNV Validation. To assess the performance of the customized array, we ap-
plied the ddPCR technology (SI Appendix, Supplemental Materials and
Methods). Several CNVs were also confirmed by analyzing read depth data
from WES using the exome hidden Markov model (56). All validated CNV
calls using this method had a quality control score >90.
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